Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
about
New perspectives in glioblastoma antiangiogenic therapyUpdate on clinical research and state of the art management of patients with advanced sarcomas and GISTIntegrative meta-analysis identifies microRNA-regulated networks in infantile hemangiomaPolypharmacology in Precision Oncology: Current Applications and Future ProspectsReview of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis.Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy.Phosphoproteomics in translational research: a sarcoma perspective.Making the Case: Intra-arterial Therapy for Less Common Metastases.Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years.Emerging drugs for the treatment of gastrointestinal stromal tumour.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.Advances and Challenges on Management of Gastrointestinal Stromal Tumors.Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumourClinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients
P2860
Q26746028-5D8CE588-45E4-4EE0-B7CB-AEBD4BCE9E33Q28073290-8E87A021-E9F4-4BC7-92C1-1C99EB708707Q29248288-4B7FE6CB-C0DA-4F02-A0C1-87819BF2E6FAQ30846907-D5132A3C-4623-45B1-9FE5-439396F9471EQ36009462-5417EA18-DFEF-4AB6-A6E0-A526F7C70848Q37423620-11BC9B8D-A91A-46F8-A972-C1382C693C4EQ38708614-AD85ED8A-05B1-4258-8461-0E5558155F95Q38745186-E24F8295-2CE4-4463-B17A-E26B3011F429Q42315791-D9304324-B842-4AFF-8399-C9B632FD3511Q47141744-921DE24C-5E8A-4FCF-8E0D-C8458A490E48Q47355982-B7C95CFF-037C-495F-B643-1ED0F908DF21Q52671439-CB1849EE-2730-4C95-8DAB-FC9C0CD7942CQ53703721-117AF227-34F0-4550-AA02-55B797E3374FQ54863183-2A7B9361-9227-431E-AB86-D5AC5470CE80Q55263134-32B99EBE-3FC7-47C4-AFEE-1332ABBFAE6FQ58753938-23FCE5CF-C932-4208-84C3-62A805703703Q58767664-2B9F5DEB-AD9A-412E-BA71-C2FC0ABCEBA4
P2860
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Nilotinib versus imatinib as f ...... ): a randomised phase 3 trial.
@ast
Nilotinib versus imatinib as f ...... ): a randomised phase 3 trial.
@en
type
label
Nilotinib versus imatinib as f ...... ): a randomised phase 3 trial.
@ast
Nilotinib versus imatinib as f ...... ): a randomised phase 3 trial.
@en
prefLabel
Nilotinib versus imatinib as f ...... ): a randomised phase 3 trial.
@ast
Nilotinib versus imatinib as f ...... ): a randomised phase 3 trial.
@en
P2093
P2860
P50
P1433
P1476
Nilotinib versus imatinib as f ...... ): a randomised phase 3 trial.
@en
P2093
Dmitry Nosov
George D Demetri
Jonathan Trent
Lilia Taningco
Peter Reichardt
Shukui Qin
Shuyuan Mo
Steven Green
P2860
P304
P356
10.1016/S1470-2045(15)70105-1
P577
2015-04-14T00:00:00Z